-
UPDATE: MLV & Co Reiterates On AmREIT On Adjusted Estimates
Monday, August 11, 2014 - 8:13am | 182Read More...In a report published Monday, MLV & Co analyst Paul Morgan reiterated a Buy rating on AmREIT (NYSE: AMRE), and raised the price target from $24.00 to $25.00. In the report, MLV & Co noted, “Following AmREIT's 2Q14 report, we are raising our price target to $25 from $24, based on rolling...
-
UPDATE: MLV & Co Reiterates On Equity One On Adjusted Estimates
Monday, August 11, 2014 - 8:13am | 94Read More...In a report published Monday, MLV & Co analyst Paul Morgan reiterated a Hold rating on Equity One (NYSE: EQY), and raised the price target from $23.00 to $24.00. In the report, MLV & Co noted, “Following Equity One's 2Q14 report, we are raising our price target to $24 from $23, based on...
-
MLV & Co Expects Third Rig To Drive Meaningful 2015 Production Growth For Callon Petroleum Company
Friday, August 8, 2014 - 8:43am | 135Read More...In a report published Friday, MLV & Co analyst Chad Mabry reiterated a Buy rating and $14.00 price target on Callon Petroleum Company (NYSE: CPE). In the report, MLV & Co noted, “CPE reported Q2'14 adj. EPS of $0.14, coming in below our $0.17 estimate but in line with consensus. Adj. EPS...
-
MLV & Co Sees Positive Momentum Going Into 2H14 For BioCryst Pharmaceuticals
Thursday, August 7, 2014 - 9:36am | 191Read More...In a report published Thursday, MLV & Co analyst Vernon T. Bernardino reiterated a Buy rating and $15.00 price target on BioCryst Pharmaceuticals (NASDAQ: BCRX). In the report, MLV & Co noted, “BioCryst Pharmaceuticals (BCRX) reported significant progress in 2Q14 highlighted by positive...
-
UPDATE: MLV & Co Reiterates On Northstar Realty Finance Following 2Q14 Dividend
Thursday, August 7, 2014 - 9:12am | 155Read More...In a report published Thursday, MLV & Co analyst Richard Eckert reiterated a Buy rating on Northstar Realty Finance (NYSE: NRF), but lowered the price target from $24.00 to $22.25. In the report, MLV & Co noted, “NRF declared a dividend of 50 cents for the second quarter of 2014. This was...
-
MLV & Co Sees In-Line Results, Solid Guidance For RLJ Lodging Trust
Wednesday, August 6, 2014 - 10:10am | 135Read More...In a report published Wednesday, MLV & Co analyst Ryan Meliker reiterated a Buy rating and $32.00 price target on RLJ Lodging Trust (NYSE: RLJ). In the report, MLV & Co noted, “RLJ reported 2Q results that were largely in-line: Adjusted EBITDA came in at $107.6mm vs. consensus of $107mm,...
-
MLV & Co Sees Solid All-Around Performance From Halcon Resources
Monday, August 4, 2014 - 10:19am | 102Read More...In a report published Monday, MLV & Co analyst Chad Mabry reiterated a Hold rating on Halcon Resources (NYSE: HK). In the report, MLV & Co noted, “We are maintaining our Hold rating at this time, although we are encouraged by HK printing another solid quarter highlighted by positive...
-
UPDATE: MLV & Co Reiterates On Dynex Capital On Mixed Factors
Thursday, July 31, 2014 - 9:34am | 153Read More...In a report published Thursday, MLV & Co analyst Richard Eckert reiterated a Hold rating on Dynex Capital (NYSE: DX), and raised the price target from $9.30 to $9.35. In the report, MLV & Co noted, “Dynex reported a largely in-line quarter for the 3 months ended June 30th, 2014. Core EPS of...
-
UPDATE: MLV & Co Reiterates On Marriott International Following Strong 2Q Results
Thursday, July 31, 2014 - 9:32am | 208Read More...In a report published Thursday, MLV & Co analyst Ryan Meliker reiterated a Hold rating on Marriott International (NASDAQ: MAR), and raised the price target from $64.00 to $67.00. In the report, MLV & Co noted, “MAR reported strong 2Q results, exceeding guidance across the board,...
-
UPDATE: MLV & Co Reiterates On Galectin Therapeutics Following Cohort 2 Results
Wednesday, July 30, 2014 - 7:41am | 216Read More...In a report published Wednesday, MLV & Co analyst Vernon T. Bernardino reiterated a Buy rating on Galectin Therapeutics (NASDAQ: GALT), but lowered the price target from $16.00 to $27.00. In the report, MLV & Co noted, “Galectin Therapeutics (GALT) this morning announced results from the...
-
UPDATE: MLV & Co Reiterates On Simon Property Group On Adjusted Estimates
Tuesday, July 29, 2014 - 7:37am | 94Read More...In a report published Tuesday, MLV & Co analyst Paul Morgan reiterated a Hold rating on Simon Property Group (NYSE: SPG), and raised the price target from $178.00 to $186.00. In the report, MLV & Co noted, “Following Simon Property's 2Q14 report, we are raising our price target to $186 from...
-
UPDATE: MLV & Co. Reiterates On Prologis Following 2Q14 Review
Wednesday, July 23, 2014 - 8:27am | 155Read More...In a report published Wednesday, MLV & Co analyst Jonathan Petersen reiterated a Hold rating on Prologis (NYSE: PLD), and raised the price target from $43.00 to $44.00. In the report, MLV & Co noted, “The warehouse market remains strong, as evidenced by the solid fundamentals underlying PLD...
-
MLV & Co Upgrades Starwood To Buy
Thursday, July 10, 2014 - 8:27am | 60Read More...Analysts at MLV & Co upgraded Starwood Hotels & Resorts Worldwide (NYSE: HOT) from “hold” to “buy.” The target price for Starwood Hotels & Resorts has been raised from $86 to $96. Starwood shares have jumped 26.12% the past 52 weeks, while the S&P 500 index has gained 18.82% in...
-
UPDATE: MLV & Co. Reiterates On TG Therapeutics On Multiple Positive Factors
Wednesday, July 2, 2014 - 9:54am | 138Read More...In a report published Wednesday, MLV & Co. analyst Graig C. Suvannavejh reiterated a Buy rating on TG Therapeutics (NASDAQ: TGTX), and raised the price target from $10.00 to $16.00. In the report, MLV & Co noted, “We now raise our PT on TGTX to $16 (vs. our prior $10) on: 1) flawless...
-
MLV & Co. Sees Asset Manager Split As Uneven For Northstar Realty Finance
Wednesday, July 2, 2014 - 8:32am | 235Read More...In a report published Wednesday, MLV & Co. analyst Richard Eckert reiterated a Buy rating and $24.00 price target on Northstar Realty Finance (NYSE: NRF). In the report, MLV & Co noted, “On Monday, NRF spun its asset manager, NorthStar Asset Management (NYSE:NSAM-$19.20-NR) and, at the same...

